



**Date: 17 December 2019**

**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **Nyrada IPO Offer Fully Subscribed**

**SYDNEY, December 17, 2019:** The Boards of both Noxopharm Ltd (ASX:NOX) and Nyrada Inc ('Nyrada') are pleased to announce that commitments for the Maximum Subscription of \$8,500,000 for the Nyrada Initial Public Offer (IPO) have been received.

The Company has been advised by the Lead Manager, Alto Capital, that the IPO Offer has been fully allocated and final reconciliation of funds are underway with formal closure of the Offer expected before Christmas.

Nyrada can confirm that the Minimum Subscription of \$7,000,000 has been received and is being held in trust.

Nyrada currently is in discussions with the ASX regarding confirmation of conditional approval requirements, however notes that further to recent ASX correspondence, conditional approval and an ASX listing of Nyrada is now expected in January 2020.

The Board will provide further updates as required.

### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda<sup>®</sup> and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

[www.noxopharm.com](http://www.noxopharm.com)

### **Investor & Corporate Enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

### **Company Secretary:**

David Franks  
T: +61 2 9299 9690  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Media queries:**

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Approval. This announcement has been approved and authorised for release by Dr Graham Kelly, Noxopharm CEO, by authority of the Noxopharm Board.